Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan-Prednisone Versus Melphalan-Prednisone in Newly Diagnosed Multiple Myeloma

被引：0

作者：

Miguel, Jesus F. San ^{[1
]}

Schlag, Rudolf ^{[2
]}

Khuageva, Nuriet K. ^{[3
]}

Dimopoulos, Meletios A. ^{[4
]}

Shpilberg, Ofer ^{[5
]}

Kropff, Martin H. ^{[6
]}

Spicka, Ivan ^{[7
]}

Petrucci, Maria Teresa ^{[8
]}

Palumbo, Antonio ^{[9
]}

Samoilova, Olga S. ^{[10
]}

Dmoszynska, Anna ^{[11
]}

Abdulkadyrov, Kudrat M. ^{[12
]}

Schots, Rik ^{[13
]}

Jiang, Bin ^{[14
]}

Mateos, Maria-Victoria ^{[15
]}

Anderson, Kenneth C. ^{[16
]}

Esseltine, Dixie-Lee ^{[17
]}

Liu, Kevin ^{[18
]}

Cakana, Andrew ^{[19
]}

van de Velde, Helgi ^{[19
]}

Richardson, Paul

机构：

[1] USAL, CSIC, IBMCC, CIC,Hosp Univ Salamanca, Salamanca, Spain

[2] Praxis Hematol & Oncol, Wurzburg, Germany

[3] SP Botkin Moscow City Clin Hosp, Dept Hematol, Moscow, Russia

[4] Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece

[5] Rabin Med Ctr, Petah Tiqwa, Israel

[6] Univ Munster, Munster, Germany

[7] Charles Univ Praha, Dept Int Med 1, Prague, Czech Republic

[8] Univ Roma La Sapienza, Rome, Italy

[9] Univ Turin, Div Ematol, AOU San Giovanni Battista, Turin, Italy

[10] Nizhnii Novgorod Reg Clin Hosp, Nizhnii Novgorod, Russia

[11] Med Univ Lublin, Lublin, Poland

[12] St Petersburg Clin Res Inst Hematol & Transfusiol, St Petersburg, Russia

[13] Belgian Hematol Soc, Myeloma Study Grp, Brussels, Belgium

[14] Peking Univ, Peoples Hosp, Beijing, Peoples R China

[15] Hosp Univ Salamanca, Salamanca, Spain

[16] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Dis Ctr, Boston, MA 02115 USA

[17] Takeda Oncol Co, Millennium Pharmaceut, Cambridge, MA USA

[18] Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA

[19] Johnson & Johnson Pharmaceut Res & Dev, Dept Clin R&D Oncol, Beerse, Belgium

来源：

BLOOD | 2008年 / 112卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：242 / 242

页数：1

共 50 条

[1] Pharmacogenomic (PGx) Analysis of Bortezomib-Associated Peripheral Neuropathy in the Phase 3 VISTA Trial of Bortezomib Plus Melphalan-Prednisone Versus Melphalan-Prednisone in Multiple Myeloma
Ricci, Deborah S.
Favis, Reyna
Sun, Yu
van de Velde, Helgi
Broderick, Erin
Meyers, Michael
Harousseau, Jean-Luc
Avet-Loiseau, Herve
Richardson, Paul G.
San Miguel, Jesus F.
BLOOD, 2009, 114 (22) : 1491 - 1491
[2] Bortezomib Plus Melphalan-Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan-Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use
Mateos, Maria-Victoria
Richardson, Paul G.
Schlag, Rudolf
Khuageva, Nuriet K.
Dimopoulos, Meletios A.
Shpilberg, Ofer
Kropff, Martin
Spicka, Ivan
Petrucci, Maria Teresa
Palumbo, Antonio
Samoilova, Olga S.
Dmoszynska, Anna
Abdulkadyrov, Kudrat M.
Schots, Rik
Jiang, Bin
Esseltine, Dixie-Lee
Liu, Kevin
Cakana, Andrew Z.
van de Velde, Heigi
San Miguel, Jesus F.
BLOOD, 2009, 114 (22) : 1484 - 1485
[3] Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
Mateos, Maria-Victoria
Richardson, Paul G.
Schlag, Rudolf
Khuageva, Nuriet K.
Dimopoulos, Meletios A.
Shpilberg, Ofer
Kropff, Martin
Spicka, Ivan
Petrucci, Maria T.
Palumbo, Antonio
Samoilova, Olga S.
Dmoszynska, Anna
Abdulkadyrov, Kudrat M.
Schots, Rik
Jiang, Bin
Esseltine, Dixie L.
Liu, Kevin
Cakana, Andrew
van de Velde, Helgi
San Miguel, Jesus F.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2259 - 2266
[4] Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
Harousseau, Jean-Luc
Palumbo, Antonio
Richardson, Paul G.
Schlag, Rudolf
Dimopoulos, Meletios A.
Shpilberg, Ofer
Kropff, Martin
Kentos, Alain
Cavo, Michele
Golenkov, Anatoly
Komarnicki, Mieczyslaw
Mateos, Maria-Victoria
Esseltine, Dixie-Lee
Cakana, Andrew
Liu, Kevin
Deraedt, William
van de Velde, Helgi
San Miguel, Jesus F.
BLOOD, 2010, 116 (19) : 3743 - 3750
[5] Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
Lee, Se Ryeon
Choi, Hojoon
Lee, Byung Hyun
Kang, Ka-Won
Yu, Eun Sang
Kim, Dae Sik
Park, Yong
Choi, Chul Won
Kim, Byung Soo
Sung, Hwa Jung
KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (06): : 1333 - 1346
[6] SUPERIOR EFFICACY WITH BORTEZOMIB PLUS MELPHALAN-PREDNISONE (VMP) VERSUS MELPHALAN-PREDNISONE (MP) ALONE IN PREVIOUSLY UNTREATED MULTIPLE MYELOMA (MM): RESULTS OF THE PHASE III MMY-3002 VISTA STUDY
San-Miguel, J.
Schlag, R.
Khuageva, N.
Dimopoulos, M.
Shpilberg, O.
Kropff, M.
Spicka, I.
Petrucci, M.
Palumbo, A.
Samoilova, O.
Dmoszynska, A.
Abdulkadyrov, K.
Schots, R.
Jiang, B.
Mateos, M.
Anderson, K.
Esseltine, D.
Liu, K.
Cakana, A.
Van de Velde, H.
Richardson, P.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 192 - 193
[7] Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma
Delforge, Michel
Terpos, Evangelos
Richardson, Paul G.
Shpilberg, Ofer
Khuageva, Nuriet K.
Schlag, Rudolf
Dimopoulos, Meletios A.
Kropff, Martin
Spicka, Ivan
Petrucci, Maria T.
Samoilova, Olga S.
Mateos, Maria-Victoria
Magen-Nativ, Hila
Goldschmidt, Hartmut
Esseltine, Dixie-Lee
Ricci, Deborah S.
Liu, Kevin
Deraedt, William
Cakana, Andrew
van de Velde, Helgi
Miguel, Jesus F. San
EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 86 (05) : 372 - 384
[8] Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan-Prednisone Versus Melphalan-Prednisone.
Harousseau, Jean-Luc
Palumbo, Antonio
Richardson, Paul
Schlag, Rudolf
Dimopoulos, Meletios A.
Shpilberg, Ofer
Kropff, Martin H.
Delforge, Michel
Schots, Rik
Cavo, Michele
Golenkov, Anatoly
Komarnicki, Mieczyslaw
Mateos, Maria-Victoria
Cakana, Andrew
Liu, Kevin
Deraedt, William
van de Velde, Helgi
Miguel, Jesus F. San
BLOOD, 2008, 112 (11) : 959 - 959
[9] Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
Facon, Thierry
Lee, Jae Hoon
Moreau, Philippe
Niesvizky, Ruben
Dimopoulos, Meletios
Hajek, Roman
Pour, Ludek
Jurczyszyn, Artur
Qiu, Lugui
Klippel, Zandra
Zahlten-Kumeli, Anita
Osman, Muhtarjan
Paiva, Bruno
San-Miguel, Jesus
BLOOD, 2019, 133 (18) : 1953 - 1963
[10] Bortezomib- melphalan-prednisone: what pattern for bortezomib in multiple myeloma?
Fouquet, Guillemette
Leleu, Xavier
HEMATOLOGIE, 2015, 21 (03): : 157 - 159

← 1 2 3 4 5 →